Multi Cancer Early Detection (MCED) Test Market - By Type, By End Use - Global Forecast, 2025 - 2034

Multi Cancer Early Detection (MCED) Test Market Size

The global multi cancer early detection test market size was valued at USD 1.5 billion in 2024. The market is expected to grow from USD 1.8 billion in 2025 to USD 5.8 billion in 2034, at a CAGR of 14.1% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is witnessing robust growth, driven by the rising global cancer burden, increasing demand for early diagnostic solutions, and rapid advancements in molecular diagnostics. MCED tests, which utilize technologies such as liquid biopsy and next-generation sequencing (NGS), offer the ability to detect multiple cancer types from a single blood sample revolutionizing traditional cancer screening paradigm.
 

This market segment plays a transformative role in reshaping cancer diagnostics by enabling earlier, more comprehensive detection of multiple cancer types through a single blood test. Leading companies such as Exact Sciences Corporation, Freenome Holdings Inc., Burning Rock Biotech Limited, Elypta AB, and AnPac Bio-Medical Science Co., Ltd. are at the forefront of this innovation-driven industry. These players maintain their competitive edge through continuous advancements in liquid biopsy technologies, integration of multi-omics data, and the application of artificial intelligence to enhance test accuracy and clinical utility. Exact Sciences’ Cancerguard test is the first commercially available MCED solution that analyzes multiple biomarker classes, offering detection for over 50 cancer types with high specificity and sensitivity
 

The MCED market is witnessing sharp growth, expanding from USD 449.2 million in 2021 to USD 1.3 billion in 2023. The growth of the market is closely tied to the escalating global burden of cancer. According to the World Health Organization (WHO), an estimated 20 million new cancer cases and 9.7 million cancer-related deaths occurred in 2022 alone. Furthermore, approximately 53.5 million people were alive within five years of a cancer diagnosis, highlighting the widespread and enduring impact of the disease. Cancer affects nearly 1 in 5 people during their lifetime, with 1 in 9 men and 1 in 12 women dying from the disease. Looking ahead, the global cancer burden is projected to rise sharply, with over 35 million new cases expected by 2050 a staggering 77% increase from 2022. This surge is driven by a combination of factors, including population ageing, population growth, and increased exposure to risk factors, many of which are linked to socioeconomic development and lifestyle changes. This alarming trend underscores the urgent need for innovative diagnostic solutions that can detect cancer early and improve survival outcomes. MCED tests are emerging as a critical tool in this context, offering the potential to identify multiple cancer types at earlier, more treatable stages.
 

Market refers to the segment of the healthcare diagnostics industry focused on the development, commercialization, and adoption of tests that can detect multiple types of cancer from a single sample typically blood before symptoms appear. These tests leverage advanced technologies such as liquid biopsy, next-generation sequencing (NGS), multi-omics analysis, and artificial intelligence to identify molecular and genetic biomarkers associated with various cancers.
 

Multi Cancer Early Detection Test Market Trends

• The MCED test market is undergoing a dynamic transformation, driven by the need for non-invasive, scalable, and multi-cancer screening solutions. Cancer remains a leading cause of death globally, accounting for nearly 10 million deaths in 2020, with common types including breast, lung, colorectal, and prostate cancers. Many of these cancers are linked to modifiable risk factors such as tobacco use, poor diet, and physical inactivity, underscoring the importance of early detection and prevention
   
• In response, diagnostic companies are developing liquid biopsy-based MCED tests that analyze circulating tumor DNA (ctDNA), RNA, and protein biomarkers from a single blood sample. These tests are increasingly being integrated into digital health platforms and electronic medical records (EMRs), enabling seamless clinical workflows and personalized screening strategies.
   
• A major trend shaping the market is the integration of artificial intelligence (AI) into diagnostic platforms. Harvard Medical School recently unveiled CHIEF (Clinical Histopathology Imaging Evaluation Foundation), a ChatGPT-like AI model capable of performing a wide range of diagnostic tasks across 19 cancer types. CHIEF analyzes digital slides of tumor tissues to detect cancer cells, predict molecular profiles, forecast patient survival, and even identify novel tumor characteristics previously unknown to clinicians. It achieved 94% accuracy in cancer detection and outperformed existing AI models by up to 36% across multiple tasks.
   
• Another major innovation shaping the market is the development of at-home MCED screening kits. The U.S. Advanced Research Projects Agency for Health (ARPA-H) launched the POSEIDON program, which funds the creation of over-the-counter multi-cancer detection kits using urine samples. These kits aim to democratize cancer screening by making it available outside clinical settings, especially for underserved populations. The program supports teams from institutions such as Carnegie Mellon University, Owlstone Medical, and Grafton Biosciences, who are working on integrating these kits with telemedicine platforms for remote diagnostics and follow-up care.
   
• As AI, multi-omics, and digital health technologies converge, MCED tests are poised to become a standard component of preventive care. Their ability to detect multiple cancers early, guide treatment decisions, and improve survival outcomes is reshaping the future of oncology diagnostics.
   

Multi Cancer Early Detection Test Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2021, the global market was valued at USD 449.2 million. The following year, it saw a slight rise to USD 779.3 million, and by 2023 the market further climbed to USD 1.3 billion.
 

Based on type, the global market is divided into gene panel, LDT, and others and liquid biopsy. The liquid biopsy segment accounted for 8.1% of the market in 2024 primarily due to their ability to detect cancer-related biomarkers from a simple blood sample, offering a minimally invasive, highly sensitive, and scalable alternative to traditional tissue biopsies. The segment is expected to exceed USD 484.3 million by 2034, growing with a CAGR of 14.3% during the forecast period. On the other hand, gene panel, LDT, and others segment is expected to grow with slightly lower CAGR of 14%. The growth of this segment is primarily driven by the widespread use of laboratory-developed tests (LDTs) which are already available in clinical settings, and the flexibility of gene panels to target specific mutations across multiple cancer types.
 

• The gene panel, LDT and others segment is the leading part of the global MCED test market, holding the largest share due to its early commercialization, clinical flexibility, and strong adoption among healthcare providers and research institutions. These tests are designed to detect multiple cancer types by analysing specific genetic mutations, methylation patterns, and other molecular signatures, making them highly effective for personalized screening strategies.
   
• Gene panel and LDT-based MCED tests are favoured for their ability to deliver accurate, customizable, and clinically validated results. They are widely used in hospitals, diagnostic labs, and specialty oncology centers, especially for cancers that lack routine screening protocols. Their compatibility with existing laboratory infrastructure and ability to target a broad range of biomarkers make them indispensable for early detection programs.
   
• Technological innovation is a key growth driver in this segment. Companies are enhancing test performance with next-generation sequencing (NGS), multi-analyte profiling, and AI-powered interpretation tools. For example, the Galleri test is a multi-cancer early detection blood test that screens for cancers before they become symptomatic.
   
• Additionally, demographic and lifestyle trends are amplifying the need for gene panel-based MCED tests. With cancer risk rising due to tobacco use, obesity, alcohol consumption, and infections particularly in low- and middle-income countries these tests offer a proactive solution for early detection and improved survival outcomes.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, multi cancer early detection test market is classified into hospitals, diagnostic laboratories, and other end users. The hospitals segment dominated the market in 2024 and is expected to reach USD 2.9 billion by 2034.
 

• Hospitals are favored for their ability to manage complex diagnostic pathways and provide multidisciplinary care. Teams of oncologists, pathologists, geneticists, and other specialists collaborate to interpret MCED test results, enhancing early detection efforts and refining treatment planning. This collaborative model ensures that MCED testing is not only accurate but also actionable within broader care strategies.
   
• The segment’s dominance is further supported by the growing emphasis on preventive healthcare. Hospitals are launching initiatives aimed at reducing late-stage cancer diagnoses, and MCED tests align perfectly with these goals by enabling early identification of multiple cancers, including those without existing screening protocols. This makes hospitals key champions of proactive cancer care.
   
• Technological innovation is also accelerating adoption. Hospitals are integrating MCED platforms with electronic medical records (EMRs), AI-powered diagnostic tools, and telemedicine systems, allowing for streamlined workflows, faster turnaround times, and personalized patient engagement. These advancements are making MCED testing more efficient and scalable across diverse healthcare settings.
   
• Additionally, hospitals benefit from centralized infrastructure and payer support, including pilot reimbursement programs and public health initiatives. Their ability to serve large patient populations and coordinate care across departments makes them essential for scaling MCED deployment and improving long-term cancer outcomes.
   

Looking for region specific data?

Download Free PDF

North America Multi Cancer Early Detection Test Market

• North America remains the leading region in the global MCED test market, driven by high awareness of preventive healthcare, strong investment in precision oncology, and early adoption of liquid biopsy and gene panel-based screening technologies. The region’s advanced healthcare infrastructure and emphasis on early diagnosis continue to fuel demand for MCED tests across hospitals, diagnostic laboratories, and wellness programs.
   
• In 2022, North America reported 2.67 million new cancer cases, 706,427 deaths, and 8.8 million prevalent cases within five years of diagnosis, underscoring the urgent need for scalable and proactive screening solutions. MCED tests are increasingly being integrated into routine health check-ups and employer-sponsored wellness initiatives, helping detect cancers before symptoms appear and improving long-term survival outcomes.
   
• North America also benefits from a well-defined regulatory and reimbursement framework, with agencies such as the U.S. FDA and CMS supporting clinical validation and pilot coverage for MCED tests. This regulatory clarity accelerates commercialization and encourages adoption among healthcare providers.
   
• Additionally, the region’s focus on multidisciplinary care—involving oncologists, pathologists, geneticists, and primary care physicians—enhances the clinical utility of MCED tests. These teams collaboratively interpret results and guide personalized treatment planning, making MCED testing a cornerstone of modern oncology workflows.
   
• As cancer risk continues to rise due to lifestyle factors North America’s proactive approach to screening and early intervention positions it as a global leader in the MCED test market.
   

The U.S. MCED test market was valued at USD 181.2 million and USD 313.7 million in 2021 and 2022, respectively. The market size reached USD 621.1 million in 2024, growing from USD 510.5 million in 2023.
 

• The U.S. remains the largest and most mature market in the global MCED test landscape, shaped by strong healthcare infrastructure, high awareness of preventive care, and early adoption of precision diagnostics. In 2025, the U.S. is projected to report 2,041,910 new cancer cases and 618,120 cancer-related deaths, highlighting the urgent need for scalable and proactive screening solutions.
   
• Healthcare providers across the U.S. are increasingly incorporating MCED tests into standard screening protocols, especially in hospitals, integrated health systems, and employer-sponsored wellness programs. These tests are being used to detect multiple cancer types including those without existing screening guidelines making them a valuable addition to routine care.
   
• The U.S. also benefits from a well-defined regulatory framework, with the FDA supporting fast-track designations and CLIA certification pathways for laboratory-developed tests (LDTs). This regulatory clarity enables faster market entry and encourages early adoption among healthcare providers.
   
• With a strong focus on multidisciplinary care, hospitals and clinics are leveraging teams of oncologists, pathologists, and geneticists to interpret MCED results and guide personalized treatment planning. This collaborative approach enhances the clinical value of MCED testing and supports its integration into mainstream oncology workflows.
   

Europe Multi Cancer Early Detection Test Market

Europe market accounted for USD 417.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe plays a central role in the global MCED test market, supported by its advanced healthcare systems, strong public investment in cancer care, and a rapidly aging population. According to WHO, cancer accounted for 20% of all deaths across the European Region, making it one of the leading causes of mortality. This alarming statistic underscores the region’s urgent need for scalable, preventive screening solutions such as MCED tests.
   
• The region is experiencing a demographic shift, with a rapidly aging population that is more susceptible to cancer and other chronic diseases. This trend is driving demand for non-invasive, scalable screening tools such as MCED tests, which can detect multiple cancers from a single blood sample and are increasingly being considered for integration into routine health assessments.
   
• European healthcare providers are gradually adopting MCED technologies, particularly in countries with strong public health infrastructure and investment in precision diagnostics. While adoption varies across member states, pilot programs and clinical trials help validate the utility of MCED tests and pave the way for broader implementation.
   
• The region also benefits from a collaborative research environment, with academic institutions, biotech startups, and public health agencies working together to advance multi-cancer detection platforms. Innovations in genomics, AI, and liquid biopsy are being explored to enhance test accuracy and accessibility.
   
• As awareness grows and clinical evidence strengthens, Europe is expected to remain a key contributor to the global MCED test market, with continued efforts to expand access, improve early diagnosis, and reduce cancer-related mortality.
   

Germany dominates the European multi cancer early detection test market, showcasing strong growth potential.
 

• Germany represents a key segment of the European MCED test market, supported by its advanced healthcare infrastructure, strong public investment in cancer care, and commitment to precision medicine. In 2022, Germany recorded 605,805 new cancer cases and 253,170 cancer-related deaths, highlighting the country’s urgent need for early detection solutions that can reduce late-stage diagnoses and improve survival outcomes.
   
• With a focus on embedding MCED tests into its public healthcare framework, Germany is actively working to include these technologies in national screening programs, setting the stage for heightened market growth. Hospitals and academic institutions are collaborating with biotech firms to validate MCED platforms and standardize clinical protocols.
   
• The country’s leadership in digital health integration, genomic research, and medical device innovation positions it as a fertile ground for MCED adoption. Healthcare providers are increasingly leveraging MCED tests to complement existing cancer screening strategies, particularly for cancers that currently lack routine screening guidelines.
   
• A robust regulatory framework, coupled with supportive government policies, facilitates the commercialization of MCED technologies. Germany’s emphasis on clinical efficacy, data security, and interoperability ensures that new diagnostic tools meet high standards and are rapidly integrated into care pathways.
   
• As Germany continues to prioritize personalized, preventive care, MCED tests are poised to play a central role in reshaping cancer diagnostics and improving long-term outcomes.
   

Asia Pacific Multi Cancer Early Detection Test Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the analysis timeframe.
 

• The Asia-Pacific region is emerging as a critical growth market in the global MCED test landscape, driven by a rising cancer incidence, growing health awareness, and expanding healthcare infrastructure. In 2022, the region accounted for 9.8 million new cancer cases, representing nearly 50% of global cancer incidence and related deaths. This underscores the urgent need for scalable, early detection solutions across diverse healthcare systems.
   
• Countries such as China, Japan, and South Korea are spearheading government-backed initiatives to promote early cancer detection, often offering subsidies or incentives for MCED test adoption. These efforts are aligned with broader public health goals to reduce late-stage diagnoses and improve survival outcomes.
   
• With a vast and aging population, coupled with escalating healthcare expenditures, the Asia-Pacific MCED market is on a rapid growth trajectory. Emerging economies such as India, Indonesia, and Vietnam present significant opportunities as they continue to invest in digital health transformation and precision medicine.
   
• As awareness of preventive care grows and healthcare systems evolve, the Asia-Pacific region is poised to become a major driver of global MCED adoption, offering immense potential for innovation, accessibility, and improved cancer outcomes.
   

China multi cancer early detection test market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China is a cornerstone of the global MCED test market, driven by its vast population, rising cancer burden, and rapid modernization of healthcare infrastructure. In 2022, China recorded 4,824,703 new cancer cases and 2,574,176 cancer-related deaths, making it one of the most affected countries globally and highlighting the urgent need for scalable early detection solutions.
   
• The country’s aging population and increasing exposure to lifestyle-related and environmental risk factors are accelerating demand for proactive cancer screening. With over 400 million people projected to be aged 60 and above by 2035, the need for non-invasive, accessible, and multi-cancer detection tools is expected to surge.
   
• China’s healthcare reforms and digital health initiatives are creating fertile ground for MCED adoption. Government-backed programs are promoting early cancer detection, and regional health authorities are beginning to explore the integration of MCED tests into public screening efforts, particularly in urban centers.
   
• With strong government support, a growing emphasis on precision medicine, and increasing public awareness of preventive care, China is poised to become a major driver of growth in the global MCED test market. The country’s scale, infrastructure, and innovation capacity make it a strategic hub for advancing multi-cancer early detection.
   

Latin American Multi Cancer Early Detection Test Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil is a leading market for MCED technologies in Latin America, driven by its large population, rising cancer burden, and expanding access to digital healthcare. In 2022, Brazil recorded 627,193 new cancer cases and 1,634,441 prevalent cases within five years, underscoring the growing need for early detection solutions that can reduce late-stage diagnoses and improve survival outcomes.
• The country’s public health system is increasingly focused on preventive care, with national initiatives aimed at improving cancer screening and expanding access to innovative diagnostics. MCED tests are gaining attention as a scalable solution to detect multiple cancers from a single blood sample, particularly in underserved and rural regions.
   
• Brazil’s National Digital Health Strategy and Precision Medicine programs are creating a favorable environment for MCED adoption. These frameworks support the integration of genomic technologies and AI-powered diagnostics into routine care, aligning with the country’s broader goals of improving healthcare equity and outcomes.
   
• As awareness grows and infrastructure improves, Brazil is poised to become a regional hub for MCED innovation and deployment, offering significant opportunities for market expansion and public health impact.
   

Middle East and Africa Multi Cancer Early Detection Test Market

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia is emerging as a strategic market for Multi-Cancer Early Detection technologies in the Middle East, driven by its expanding oncology infrastructure, robust public health initiatives, and alignment with Vision 2030’s goals for preventive and personalized care.
   
• According to WHO data, the country recorded 28,113 new cancer cases in 2022, with breast, colorectal, and thyroid cancers among the most prevalent. This rising cancer burden has accelerated demand for innovative screening solutions capable of detecting multiple cancers at early, asymptomatic stages.
   
• Saudi Arabia’s healthcare transformation under Vision 2030 emphasizes digital health, public-private partnerships, and equitable access to care creating fertile ground for MCED deployment. The Health Sector Transformation Program (HSTP) has prioritized early detection and screening as core pillars, with initiatives aiming to reduce late-stage diagnoses through streamlined, tech-enabled workflows.
   
• With cancer rates projected to rise in the GCC, Saudi Arabia is positioning itself as a regional hub for MCED innovation, combining clinical excellence with scalable screening infrastructure. The integration of MCED tests into national screening programs and hospital networks is expected to significantly improve survival outcomes and reduce long-term healthcare costs.
   

Multi Cancer Early Detection Test Market Share

The MCED test market is shaped by a mix of pioneering global leaders and emerging innovators, resulting in a rapidly evolving competitive landscape. The top five companies GRAIL, Inc. (Illumina, Inc.), Guardant Health, Exact Sciences Corporation, Freenome Holdings, and Burning Rock Biotech collectively account for 65% of the global market share, driven by their advanced biomarker platforms, robust clinical validation, and aggressive commercialization strategies.
 

To strengthen their market positions, these leading firms are pursuing multi-pronged approaches including strategic partnerships with healthcare systems, collaborations with national cancer institutes, and expansion into high-burden cancer regions. Their focus on liquid biopsy, multiomic analysis, and AI-powered tissue-of-origin prediction is enabling earlier, more accurate, and less invasive cancer detection across diverse populations.
 

 In addition to these dominant players, companies such as SeekIn, Singlera Genomics, Elypta, and Genecast Biotechnology are contributing to market growth through novel biomarker discovery, region-specific validation studies, and differentiated technology platforms. Their presence is particularly notable in Asia-Pacific and Europe, where rising cancer incidence and supportive regulatory frameworks are accelerating MCED adoption.
 

Overall, the market is witnessing intensified competition and greater technological diversity, as both established and emerging players continue to innovate and scale their offerings to meet the global demand for accessible, high-performance cancer screening solutions.
 

Multi Cancer Early Detection Test Market Companies

Prominent players operating in the MCED test industry are as mentioned below:

• AnPac Bio-Medical Science
• Burning Rock Biotech
• EarlyDiagnostics
• Elypta
• EXACT SCIENCES CORPORATION
• Freenome Holdings
• Genecast Biotechnology
• Guangzhou AnchorDx Medical
• GUARDANT HEALTH
• Harbinger Health
• GRAIL
• Micronoma
• SeekIn
• Singlera Genomics
• GRAIL
   

GRAIL is a leader in the MCED market, known for its flagship product Galleri, a blood-based test capable of detecting signals from over 50 cancer types. The company leverages advanced cfDNA methylation profiling and machine learning to deliver high-accuracy, early-stage cancer detection. GRAIL’s strong clinical validation and commercial rollout through partnerships and health systems have positioned it at the forefront of precision oncology.
 

• Freenome Holdings

Freenome is a prominent player in the MCED market, leveraging its proprietary multiomics platform to detect cancer through a combination of genomic, proteomic, and immune system signals. The company is focused on developing non-invasive, blood-based screening tests for multiple cancer types, with colorectal and lung cancer as its initial targets. Through large-scale clinical trials and strategic partnerships with industry leaders such as Exact Sciences, Freenome is advancing the future of early cancer detection and personalized screening.
 

• Genecast Biotechnology

Genecast Biotechnology is an emerging player in the MCED market, recognized for its THEMIS test designed for early detection and localization of multiple high-incidence cancers. The test uses whole-methylome sequencing (WMS) and a multimodal ensemble model to generate a cancer probability score. In clinical validation, THEMIS demonstrated 86% overall sensitivity at 99% specificity, with strong performance in early-stage cancers (72% for stage I and 81% for stage II).
 

Multi Cancer Early Detection Test Industry News

• In October 2024, SeekIn Inc. presented a cost-effective two-step multi-cancer screening strategy and a breakthrough lung cancer early detection test at the early detection of cancer conference in San Francisco. The proposed strategy combines low-cost initial screening with a high-specificity follow-up test, aiming to improve accessibility and reduce false positives in population-wide cancer screening. SeekIn also unveiled new data on its lung cancer test, which demonstrated high sensitivity in detecting early-stage disease using blood-based biomarkers. These innovations reinforce SeekIn’s commitment to scalable, affordable, and clinically validated MCED solutions, particularly for use in public health programs and emerging markets.
   
• In June 2024, Illumina, Inc. officially completed the spin-off of GRAIL, making it an independent, publicly traded company under the ticker GRAL on Nasdaq. This move followed years of antitrust scrutiny from U.S. and European regulators. Illumina now holds a 14.5% minority stake in GRAIL and continues to support it with sequencing technology and services. The divestiture allows GRAIL to pursue its mission independently, focusing on regulatory approvals, payer coverage, and broader commercialization.
   

The MCED test market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Gene panel, LDT and others
• Liquid biopsy

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Other End Use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE